Blog

Nathan A. Pennell: Pralsetinib development outside the US and China also stopped

Photo from Nathan A. Pennell/X

Jan 13, 2024, 10:04

Nathan A. Pennell: Pralsetinib development outside the US and China also stopped

Nathan A. Pennell, Co-Director of the Cleveland Clinic Lung Cancer Program, shared a post by EGFR Resisters on X/Twitter:

“Oh man, pralsetinib (for RET+ tumors) development outside the US and China also stopped. Hope this gets resumed with new partners.”

Quoting EGFR Resisters’s post:

“Blueprint Medicines issued press release: “Discontinue further investment in the early clinical stage therapies BLU 945 and 451 for EGFR Non-Small Cell Lung Cancer and explore strategic options including potential outlicensing” Blu-945 and Blu-451 clinical trials will close.”

Read further.

Source: Nathan A. Pennell/X and EGFR Resisters/X

Blu-451 Blu-945 Blueprint Medicines cancer Cleveland Clinic EGFR Resisters Nathan A.Pennell non small cell lung cancer NSCLC OncoDaily Oncology pralsetinib RET

In Memory of Alan Rickman and His Battle with Prostate and Pancreatic Cancer

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Oncologist Near Me – Nazik Hammad: A Leader in Cancer Care, Medical Education, and Health Equity

Garo Armen - A Bold Call to Action: Embracing Real-Time Innovation in Pediatric Cancer